Arjun V. Balar
Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer.
Overview
Arjun Balar led KEYNOTE-052 and the cisplatin-ineligible cohort of IMvigor210, the studies that gave pembrolizumab and atezolizumab their first-line approvals in urothelial cancer for patients who cannot receive cisplatin, and KEYNOTE-057 in BCG-unresponsive non-muscle-invasive disease. He continues to lead combination and bladder-preservation trials at NYU.
Pages like this
not linked directly; found by shared links- PersonJoaquim Bellmunt
Shares Bladder & urothelial cancer, Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
- PersonJonathan E. Rosenberg
Shares Atezolizumab, PD-L1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
- PersonDean F. Bajorin
Shares Bladder & urothelial cancer, PD-1, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
- PersonMartin Reck
Shares Atezolizumab, Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonPeter Schmid
Shares Atezolizumab, PD-L1, Pembrolizumab, PD-1 and the tag immunotherapy.
- PersonGordon J. Freeman
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonTimothy F. Cloughesy
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonLieping Chen
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.